CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...

This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...

This week, mRNA vaccines are set to face intense scrutiny from critics in Congress. Here's an explainer of how we know they ...

The revised version of the vaccine, marketed as Spikevax, follows FDA guidance recommending that this year’s shots target ...

Moderna, Inc. (Nasdaq:MRNA), today announced that in consultation with the U.S. Food and Drug Administration (FDA), the Company has voluntarily withdrawn the pending Biologics License Application (BLA ...

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were instrumental in saving lives during the COVID pandemic.

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

The FDA announced yesterday that it will limit access to Covid-19 vaccines to people 65 years of age and older and others who ...

The US Food and Drug Administration is changing the way it approves Covid-19 vaccines for Americans, a move that may limit ...

The company did not grant an interview to talk about its nanoparticle development, and neither did Pfizer or BioNTech. For its COVID-19 vaccine, Moderna ultimately used an ionizable lipid that it ...

Fuelled with the windfall cash from its massively successful COVID-19 shot, Moderna has been accelerating development of its R&D pipeline, focusing on vaccines for other respiratory diseases ...